TITLE

FDA denies chemoprevention indication for dutasteride

PUB. DATE
February 2011
SOURCE
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p3
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of the U.S. Food and Drug Administration (FDA) to deny the application submitted by GlaxoSmithKline for its prostate cancer chemoprevention drug dutasteride.
ACCESSION #
62393611

 

Related Articles

  • Chemoprevention being examined as prostate cancer tx. Sieve, Vonne // Urology Times;May98, Vol. 26 Issue 5, p34 

    Examines the use of chemoprevention in prostate cancer treatment. Information on chemoprevention; Process of chemoprevention; Effect of the anti-androgen in prostate cancer.

  • Strategies for chemoprevention of prostate cancer. Kelloff, G J; Lieberman, R; Brawer, M K; Crawford, E D; Labrie, F; Miller, G J // Prostate Cancer & Prostatic Diseases;1999 Supplement 1, Vol. 2 Issue 1, p27 

    Because prostate cancer has a long latency and high incidence, it is a good target for chemoprevention by agents such as retinoids, antiandrogens, antiestrogens, and vitamin D analogs. Phase II chemoprevention trials are frequently conducted on cohorts of patients with previous cancers or...

  • Androgen deprivation as a strategy for prostate cancer chemoprevention. Aquilina, Joseph W.; Lipsky, James J. // JNCI: Journal of the National Cancer Institute;05/21/97, Vol. 89 Issue 10, p689 

    Opinion. Looks at androgen deprivation as an option in prostate cancer chemoprevention. Selection of suitable androgen-deprivation chemopreventive agents; Surrogate end-point biomarkers; Target populations for prostate cancer chemoprevention.

  • ODAC rejects dutasteride, dutasteride for prostate cancer prevention.  // Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p1 

    The article reports on the rejection of an application to approve GlaxoSmithKline's dutasteride and Merck's finasteride for prostate cancer chemoprevention.

  • The influence of dietary and environmental factors on prostate cancer risk. Kooiman, G G; Martin, F L; Williams, J A; Grover, P L; Phillips, D H; Muir, G H // Prostate Cancer & Prostatic Diseases;2000, Vol. 3 Issue 4, p256 

    Prostate cancer is the most common malignancy found in males and one of the most common causes of cancer death. The epidemiology implicates environmental and nutritional factors in the initiation and progression of the disease. Identification of these factors would allow chemoprevention...

  • Curcumin Shows Chemopreventive Potential for Prostate Cancer. Finkel, Jon // Life Extension;Mar2010, Vol. 16 Issue 3, Special section p2 

    The article discusses research indicating that curcumin may interfere with prostate cancer proliferation and metastasis.

  • Anti-androgenic effects of flavonols in prostate cancer. Boam, Tristan // Ecancermedicalscience;2015, Vol. 9 Issue 577-607, p1 

    Dietary-derived agents, such as the flavonoids, are of particular interest for prostate cancer (PCa) chemoprevention as they may offer a favourable safety and side-effect profile. An agent that demonstrates action on the androgen receptor (AR) axis may have value for preventing or treating...

  • Chemoprewencja raka stercza -- nowe perspektywy? JabÅ‚onowski, Zbigniew // Polish Journal of Urology / Urologia Polska;2008, Vol. 61 Issue 3, p202 

    In Poland the amount of newly diagnosed prostate cancers increases systematically with the number of 7095 cases in 2005. It is estimated that 200 000 men are diagnosed with prostate cancer in the USA annually and about 90% of them receive treatment for it. The Prostate Cancer Prevention Trial...

  • Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer? Goeman, L.; Joniau, S.; Ponette, D.; Van der Aa, F.; Roskams, T.; Oyen, R.; Van Poppel, H. // Prostate Cancer & Prostatic Diseases;2003, Vol. 6 Issue 4, p305 

    Introduction: High-grade prostatic intraepithelial neoplasia (HGPIN) is generally accepted to be a precursor lesion of prostate cancer. The likely outcome of isolated low-grade PIN (LGPIN) lesions in prostate biopsies remains unclear. A follow-up study of 106 patients with LGPIN- and HGPIN...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics